We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Immunomedics has reported encouraging results from its Phase I/II trial with
its compound, epratuzumab, for the treatment of Sjogren's syndrome, an autoimmune
disease that currently affects between 2 to 4 million Americans.
Genentech, Biogen Idec and Roche have announced preliminary positive results
from a large randomized clinical trial of Rituxan in rheumatoid arthritis (RA)
showing that a greater proportion of patients treated with a single course of
Rituxan, with a stable dose of methotrexate (MTX), achieved American College
of Rheumatology (ACR) 20, 50 and 70 response rates compared to placebo.
Antigenics has announced that Oncophage (HSPPC-96), an investigational personalized
cancer vaccine, has been granted orphan-drug status for the treatment of renal
cell carcinoma (RCC, the most common type of kidney cancer) by the European
Medicines Agency.
Lorus Therapeutics has announced that the European Medicines Agency has given
a positive opinion on Lorus' application for orphan-drug status to Virulizin,
the company's lead anticancer drug for the treatment of pancreatic cancer.
Vical has announced that Merck & Co. has exercised three options under a
2003 amendment to an existing research collaboration and license agreement,
granting Merck rights to use Vical's patented nonviral gene delivery technology
in cancer vaccine applications.
Novavax has announced additional positive results from preclinical studies applying
its proprietary micellar nanoparticle (MNP) technology to transdermally deliver
two nonhormone drugs.
Rheumatoid arthritis (RA) patients whose joint damage was inhibited through
a combination therapy of HUMIRA (adalimumab) and methotrexate (MTX) early in
the course of their disease were less likely to experience further damage two
years later, according to a new Abbott study.
Neurologix has announced the completion of all neurosurgical gene transfer procedures
in its landmark, 12-patient, dose-escalating Phase I clinical trial of gene
therapy for Parkinson's disease.